Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.
dan2021-12-10T14:29:03-05:00Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc's (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products. Read Article: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/cingulate-inc-announces-pricing-25-020500801.html
Stay In Touch